AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17060062
Drug: glibenclamide 3.5
RxNorm normalized name: Glibenclamide 3.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glibenclamide 3.5 mg
Trial: 11426360
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone (50 microg/kg during 10 minutes followed by 0.5 microg/kg/min)
Trial: 11426360
Drug: Intravenous dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dobutamine (10 to 20 microg/kg/min)
Trial: 8435895
Drug: Continuous 24-hour
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 24-hour infusion of 2 IU GH
Trial: 8435895
Drug: Two intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two intravenous boluses of 2 IU GH
Trial: 8435895
Drug: Eight intravenous
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight intravenous boluses of 2 IU GH every 3 hours
Trial: 8435895
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection of 0.2 U/kg GH
Trial: 18450928
Drug: Neurocognition and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocognition and symptom measures during treatment
Trial: 12637464
Drug: Arzoxifene 20
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arzoxifene 20 mg
Trial: 12637464
Drug: Arzoxifene 50
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arzoxifene 50 mg
Trial: 11131781
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of oral misoprostol (400 microg)
Trial: 19843783
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg lidocaine 2% plus 10 microg fentanyl (Group I)
Trial: 19843783
Drug: Intrathecal 3
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal 3 mg levobupivacaine 0.5% plus 10 microg fentanyl (Group II)
Trial: 17199533
Drug: Autologous fibroblast
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous fibroblast injections
Trial: 15262418
Drug: Nystatin incorporated
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nystatin incorporated into gel and suspension formulations
Trial: 15262418
Drug: Chitosan gel
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan gel alone
Trial: 15262418
Drug: Nystatin formulations
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nystatin formulations
Trial: 9609412
Drug: Enteral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral ciprofloxacin 750 mg b.i.d.
Trial: 9609412
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin 400 mg b.i.d.
Trial: 3185292
Drug: Conjugated oestrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated oestrogens 1.25 mg
Trial: 3185292
Drug: Oestradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol valerate 2 mg
Trial: 31230222
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of donepezil hydrochloride and choline supplement
Trial: 28351897
Drug: Sensor-augmented insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensor-augmented insulin pump with PLGM OFF
Trial: 24802530
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with adapalene 0.1% gel and ketoconazole 2% cream once daily for 2 weeks
Trial: 24802530
Drug: Ketoconazole 2%
RxNorm normalized name: KETOCONAZOLE 2% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 2% cream twice daily for 2 weeks (monotherapy group)
Trial: 23331844
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg testosterone undecanoate (n = 10)
Trial: 12477584
Drug: rapacuronium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rapacuronium 0.25 mg x kg(‐1) i.v. (Group 1)
Trial: 12477584
Drug: rapacuronium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rapacuronium 0.5 mg x kg(‐1) i.v. (Group 2)
Trial: 12477584
Drug: rapacuronium 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rapacuronium 0.75 mg x kg(‐1) i.v. (Group 3)
Trial: 7637161
Drug: Flumazenil (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.2 mg‐1.0 mg)
Trial: 29507124
Drug: Intensive audit
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive audit and feedback with daily-updated team-based data dashboard and weekly in-person review of performance data ('STAT rounds')
Trial: 29507124
Drug: Usual audit
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual audit and feedback with ongoing twice-monthly emails with graphical depictions of team performance
Trial: 25337035
Drug: RBC transfusion
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC transfusion at a Hb threshold of 8.9 g/dL (liberal group)
Trial: 25337035
Drug: RBC transfusion
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC transfusion at a Hb threshold of 7.3 g/dL (restrictive group)
Trial: 12946740
Drug: Alfuzosin 5
RxNorm normalized name: alfuzosin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 5 mg twice daily
Trial: 12946740
Drug: Control/Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control/Standard therapy
Trial: 20235087
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate loading; 61.0% compliance in audit group vs 96% in trial group; P < 0.001
Trial: 20235087
Drug: Non-opiate postoperative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opiate postoperative oral analgesia; 70.0% in audit group vs 99% in trial group; P < 0.001
Trial: 12519102
Drug: Oxcarbazepine (OXC)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OXC) at a final dose of 900-2100 mg for 14 days, followed by 7 days without OXC, then 14 days back on OXC.
Trial: 344019
Drug: M‐‐M (decreasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐‐M (decreasing daily dose of methadone in two equal doses given 12 hours apart)
Trial: 344019
Drug: M‐‐PN (decreasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐‐PN (decreasing daily dose of methadone supplemented by propoxyphene napsylate)
Trial: 31096538
Drug: Single-dose rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose rectal indomethacin administration
Trial: 31096538
Drug: Double-dose rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose rectal indomethacin administration
Trial: 24362706
Drug: CocoaCHOC: 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CocoaCHOC: 350 mg flavanols per serving
Trial: 24362706
Drug: CHOC: 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOC: 0 mg flavanols
Trial: 9454350
Drug: CHARTWEEL radiotherapy
RxNorm normalized name: carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHARTWEEL radiotherapy to 60 Gy (15 weekly fractions of 1.5 Gy)
Trial: 9454350
Drug: Conventional fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionated radiotherapy to 66 Gy (5 weekly fractions of 2 Gy)
Trial: 8094114
Drug: Gentamicin 4
RxNorm normalized name: gentamicin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 4 mg/kg once daily (OD)
Trial: 8094114
Drug: Gentamicin 1.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 1.33 mg/kg three times daily (MD)
Trial: 31856887
Drug: Twice-daily nebulised
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily nebulised hypertonic saline (HTS 6%) with standard care
Trial: 31856887
Drug: Carbocisteine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day) with standard care
Trial: 31856887
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of twice-daily nebulised HTS and carbocisteine with standard care
Trial: 29373476
Drug: MEDI8897 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI8897 50 mg
Trial: 23025349
Drug: Prolonged-release oxycodone/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release oxycodone/naloxone (OXN PR) tablets (20/10 mg) with slow, medium, and fast dissolution rates.
Trial: 23025349
Drug: Prolonged-release oxycodone/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release oxycodone/naloxone (OXN PR) tablets (20/10 mg) with varying dissolution rates.
Trial: 20595477
Drug: IV-ibuprofen 400
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV-ibuprofen 400 mg every 6 hours for 72 hours
Trial: 8863236
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (rhGH, 0.2 mg/kg/d)
Trial: 1321655
Drug: Flunarizine 10
RxNorm normalized name: flunarizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine 10 mg
Trial: 6547612
Drug: Intrathecal cinchocaine
RxNorm normalized name: cinchocaine
DrugBank: Cinchocaine (DB00527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal cinchocaine with morphine hydrochloride 2.5 mg
Trial: 3453169
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care (SC) treatment
Trial: 3453169
Drug: Referred care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referred care (RC) treatment
Trial: 29251700
Drug: Low Molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Molecular Weight Heparin (LMWH) 30 mg BID
Trial: 29251700
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg BID
Trial: 23913744
Drug: Prior ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior ketoconazole therapy
Trial: 21939418
Drug: Once-weekly recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly recombinant factor VIII prophylaxis, with up to two rescue doses per week
Trial: 21939418
Drug: Thrice-weekly prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly prophylaxis
Trial: 11991797
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (paretic arm and leg immobilized)
Trial: 2655259
Drug: Short-term intravesical
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intravesical therapy (STIT) with 1% solution of Epodyl, given once per week for 6 weeks
Trial: 2655259
Drug: Long-term intravesical
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term intravesical therapy (LTIT) with 1% solution of Epodyl, consisting of STIT followed by an additional dose once a month for 2 years
Trial: 2655259
Drug: Short-term intravesical
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intravesical therapy (STIT) for solitary tumors
Trial: 2655259
Drug: Long-term intravesical
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term intravesical therapy (LTIT) for solitary tumors
Trial: 875786
Drug: Viloxazine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine (100 mg three times a day)
Trial: 875786
Drug: Imipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (50 mg three times a day)
Trial: 20525780
Drug: 4-mg nicotine
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg nicotine lozenge with behavioral intervention
Trial: 18427418
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (VC: 1 000 mg vitamin C)
Trial: 16153930
Drug: Aspirin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (150 mg orally 12 and 3 hours before surgery)
Trial: 10613576
Drug: Levodopa 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 5, 10, or 20 mg (for children <40 kg) or 10, 20, or 40 mg (for children ≥40 kg) 3 times a day
Trial: 10613576
Drug: Levodopa/carbidopa combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa combination
Trial: 7562679
Drug: Standardized sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized sodium diet with water loading (2290 ml in 3 1/2 hr) and competitive videogame stress test
Trial: 27801407
Drug: Intravascular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular laser irradiation of blood (daily 25 min sessions for 7 days, 2 MW, 0.63 microns)
Trial: 27801407
Drug: Pharmacotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy alone (control group)
Trial: 16111588
Drug: Alternating triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating triple therapy (ATT)
Trial: 10819233
Drug: Erythromycin 400
RxNorm normalized name: ERYTHROMYCIN 400 mg in 5.2 g TOPICAL POWDER [API E.M ERYTHROMYCIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 400 mg orally three times a day for 1 week
Trial: 10819233
Drug: Erythromycin 200
RxNorm normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 200 mg orally three times a day for 4 weeks
Trial: 10819233
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin 10 mg x kg(‐1) x h(‐1)
Trial: 7038165
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of sulfisoxazole
Trial: 7038165
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of sulfisoxazole
Trial: 7038165
Drug: trimethoprim 160
RxNorm normalized name: trimethoprim 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim 160 mg and sulfamethoxazole 800 mg
Trial: 7038165
Drug: trimethoprim 320
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: trimethoprim 320 mg and sulfamethoxazole 1,600 mg
Trial: 31319590
Drug: Cod protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod protein hydrolysate (CPH) 2.5 g daily for 6 weeks
Trial: 27717236
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 28,000 IU once weekly for 24 weeks
Trial: 22949149
Drug: High-dose (≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (≥ 30 Gy) thoracic radiation (n = 38)
Trial: 22949149
Drug: Lower-dose (<
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose (< 30 Gy) thoracic radiation combined with anthracycline (n = 24)
Trial: 22949149
Drug: Higher thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher thoracic radiation dose
Trial: 15749317
Drug: Cefuroxime administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime administered intravascularly as a bolus dose of 1.5 g
Trial: 8508193
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) condition with increased carbohydrate intake from 5.8 to 8.8 g kg‐1 BW, supplemented with a 16.5% glucose polymer solution.
Trial: 3691011
Drug: Unflavored oral
RxNorm normalized name: potassium bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unflavored oral suspension (20 mg/mL)
Trial: 3691011
Drug: Tablets (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets (two 200-mg tablets)
Trial: 3691011
Drug: Flavored and
RxNorm normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavored and unflavored carbamazepine suspensions
Trial: 30557965
Drug: Low-dose MDCT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MDCT (ldMDCT)
Trial: 30557965
Drug: Standard-dose MDCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose MDCT (sdMDCT)
Trial: 27420732
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT) with a 940 nm diode laser, energy of 4 J/cm² applied to one side immediately after surgery
Trial: 25142813
Drug: Edaravone (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone (intravenous 30 mg twice per day for 2 weeks)
Trial: 17873681
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus rivastigmine
Trial: 17873681
Drug: Rivastigmine plus
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine plus fluoxetine
Trial: 10520836
Drug: i.v. pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. pantoprazole (20, 40, 80, or 120 mg)
Trial: 10520836
Drug: i.v. pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. pantoprazole (80 and 120 mg)
Trial: 10520836
Drug: i.v. famotidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. famotidine (20 mg)
Trial: 23085503
Drug: Sertraline (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (initial dose of 50mg once daily, with dose escalation to a maximum of 200mg)
Trial: 23085503
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo to sertraline)
Trial: 17468863
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg, twice daily
Trial: 17468863
Drug: Tegaserod 6
RxNorm normalized name: tegaserod 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 6 mg, twice daily plus esomeprazole 40 mg, once daily
Trial: 17468863
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg, once daily
Trial: 14735174
Drug: Infusion topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion topotecan
Trial: 11504276
Drug: FFR‐rFVIIa (0.01,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFR‐rFVIIa (0.01, 0.02, 0.05, 0.08, 0.12, 0.18, 0.27, or 0.40 mg/kg body weight)
Trial: 1983508
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) Fragmin
Trial: 1983508
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin Calciparin
Trial: 304126
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (354 patients)
Trial: 31842969
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM), 10 g/packet, twice daily for 2 weeks
Trial: 31842969
Drug: CM placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM placebo, 10 g/packet, twice daily for 2 weeks
Trial: 15264186
Drug: postdilution HDF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: postdilution HDF, 20 L, with FX80
Trial: 15264186
Drug: predilution HDF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: predilution HDF, 20 L, with FX80
Trial: 15264186
Drug: predilution HDF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: predilution HDF, 60 L, with FX80
Trial: 11578788
Drug: Atorvastatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin plus vitamin C and vitamin E
Trial: 9745160
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: DeNol 120 mg, amoxicillin 500 mg and metronidazole 250 mg four times a day orally for 14 days